Literature DB >> 12388236

Acetylcholine but not adenosine triggers preconditioning through PI3-kinase and a tyrosine kinase.

Qining Qin1, James M Downey, Michael V Cohen.   

Abstract

Adenosine and acetylcholine (ACh) trigger preconditioning by different signaling pathways. The involvement of phosphatidylinositol 3-kinase (PI3-kinase), a protein tyrosine kinase, and Src family tyrosine kinase in preconditioning was evaluated in isolated rabbit hearts. Either wortmannin (PI3-kinase blocker), genistein (tyrosine kinase blocker), lavendustin A (tyrosine kinase blocker), or 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol[3,4-d]pyrimidine (PP2; Src family tyrosine kinase blocker) was given for 15 min to bracket a 5-min infusion of either adenosine or ACh (trigger phase). The hearts then underwent 30 min of regional ischemia. Infarct size for ACh alone was 9.3 +/- 3.5% of the risk zone versus 34.3 +/- 4.1% in controls. All four inhibitors blocked ACh-induced protection. When wortmannin or PP2 was infused only during the 30-min ischemic period (mediator phase), ACh-induced protection was not affected (7.4 +/- 2.1% and 9.7 +/- 1.7% infarction, respectively). Adenosine-triggered protection was not blocked by any of the inhibitors. Therefore, PI3-kinase and at least one protein tyrosine kinase, probably Src kinase, are involved in the trigger phase of ACh-induced, but not adenosine-induced, preconditioning. Neither PI3-kinase nor Src kinase is a mediator of the protection of ACh.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388236     DOI: 10.1152/ajpheart.00476.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  11 in total

1.  Changes in the loading conditions induced by vagal stimulation modify the myocardial infarct size through sympathetic-parasympathetic interactions.

Authors:  Bruno Buchholz; Martín Donato; Virginia Perez; Ana Clara Rey Deutsch; Christian Höcht; Julieta S Del Mauro; Manuel Rodríguez; Ricardo J Gelpi
Journal:  Pflugers Arch       Date:  2014-08-17       Impact factor: 3.657

2.  Protein kinase Cepsilon interacts with cytochrome c oxidase subunit IV and enhances cytochrome c oxidase activity in neonatal cardiac myocyte preconditioning.

Authors:  Mourad Ogbi; John A Johnson
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 3.  Myocardial ischemic conditioning: Physiological aspects and clinical applications in cardiac surgery.

Authors:  Radhouane Bousselmi; Mohamed Anis Lebbi; Mustapha Ferjani
Journal:  J Saudi Heart Assoc       Date:  2013-11-13

4.  Preconditioning-mimetics bradykinin and DADLE activate PI3-kinase through divergent pathways.

Authors:  Michael V Cohen; Sebastian Philipp; Thomas Krieg; Lin Cui; Atsushi Kuno; Viktoriya Solodushko; James M Downey
Journal:  J Mol Cell Cardiol       Date:  2007-01-10       Impact factor: 5.000

5.  Ischaemic tolerance in aged mouse myocardium: the role of adenosine and effects of A1 adenosine receptor overexpression.

Authors:  John P Headrick; Laura Willems; Kevin J Ashton; Kirsten Holmgren; Jason Peart; G Paul Matherne
Journal:  J Physiol       Date:  2003-04-25       Impact factor: 5.182

6.  Sustained ligand-activated preconditioning via δ-opioid receptors.

Authors:  Jason N Peart; Louise E See Hoe; Garrett J Gross; John P Headrick
Journal:  J Pharmacol Exp Ther       Date:  2010-10-14       Impact factor: 4.030

Review 7.  Signaling pathways in ischemic preconditioning.

Authors:  James M Downey; Amanda M Davis; Michael V Cohen
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

Review 8.  Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.

Authors:  Michael V Cohen; James M Downey
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

9.  Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling.

Authors:  Jennifer L Strande; Anna Hsu; Jidong Su; Xiangping Fu; Garrett J Gross; John E Baker
Journal:  J Pharmacol Exp Ther       Date:  2007-11-30       Impact factor: 4.030

10.  Bag-1L Protects against Cell Apoptosis in an In Vitro Model of Lung Ischemia-Reperfusion Injury through the C-Terminal "Bag" Domain.

Authors:  Ji-Ling Lv; Li-Na Shi; Cong-Ying Zhai; Ge-Jin Wang; Yan Qu
Journal:  Biomed Res Int       Date:  2021-03-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.